1. Home
  2. KRUS vs CUVL Comparison

KRUS vs CUVL Comparison

Compare KRUS & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

N/A

Current Price

$23.20

Market Cap

459.1M

ML Signal

N/A

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$4.80

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
KRUS
CUVL
Founded
2008
1999
Country
United States
Australia
Employees
N/A
N/A
Industry
Restaurants
Miscellaneous
Sector
Consumer Discretionary
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
459.1M
374.2M
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
KRUS
CUVL
Price
$23.20
$4.80
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $43.86
N/A
AVG Volume (30 Days)
★ 297.5K
5.5K
Earning Date
01-06-2027
08-27-2026
Dividend Yield
N/A
★ 0.59%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $328,276,000.00
N/A
Revenue This Year
$15.09
$0.47
Revenue Next Year
$17.22
$6.25
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 16.10
N/A
52 Week Low
$23.47
$4.81
52 Week High
$80.84
$8.20

Technical Indicators

Market Signals
Indicator
KRUS
CUVL
Relative Strength Index (RSI) 28.55 34.70
Support Level N/A N/A
Resistance Level $59.30 $6.00
Average True Range (ATR) 2.18 0.23
MACD -0.66 0.01
Stochastic Oscillator 0.03 0.76

Price Performance

Historical Comparison
KRUS
CUVL

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: